ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
Stock Information for ClearPoint Neuro, Inc.
Loading
Please wait while we load your information from QuoteMedia.